Khartis Therapeutics
Khartis Therapeutics Raises $50M Series B for Oral Immunology Medicines
Khartis Therapeutics announced $50M in Series B financing on August 13, 2026. Khartis Therapeutics raised a $50 million Series B led by Forge Life Science Partners to advance its oral IGF-1R inhibitor for thyroid eye disease.
Round details
The financing includes backing from Forge Life Science Partners, Longwood Fund, Alexandria Venture Investments, Foresite Capital, Lilly Asia Ventures, Nextech Invest. The company did not publish a valuation with the announcement.
- Round: Series B
- Capital announced: $50M
- Total funding reported: $95M
- Headquarters: San Diego, CA
How the company plans to use the capital
Khartis will use the financing to advance its lead program, an oral, selective IGF-1R inhibitor for thyroid eye disease, and to continue developing its broader pipeline of oral small molecule medicines targeting clinically validated immunology pathways.
Why this matters for GTM teams
Existing investors Foresite Capital, Lilly Asia Ventures and Nextech Invest took part in the round, which brought total capital raised to $95 million. Chief Scientific Officer Craig Murphy said existing thyroid eye disease treatments come with real safety tradeoffs.
Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.
Source and methodology
This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.
Primary source: Khartis Therapeutics Series B announcement.
Company Info
Investors (6)
Share
Related Reports
Infisical Raises $40M Series B for AI Agent Security Infrastructure
Infisical raised a $40 million Series B at a $600 million valuation, led by Elad Gil, to expand security infrastructure for AI agents.
Vera Health Raises $28.5M Series A for Clinical AI Search
Vera Health raised a $28.5 million Series A led by Threshold Ventures to further develop its clinical evidence infrastructure and expand into additional healthcare markets.
Omnichat Raises US$10M Series A for Agentic Customer Experience Platform
Omnichat raised a US$10 million Series A led by Openspace Capital to scale its agentic AI platform, deepen R&D on Omni AI Agents and expand globally.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free